Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer
By N. Ferrara, Kenneth J. Hillan, H. Gerber, W. Novotny. Nature reviews. Drug discovery, 2004
2,638 citations recorded by the source corpus.
Subfields: Cancer Research, Molecular Biology, Oncology
View Paper: https://www.semanticscholar.org/paper/b49795dfc6a855137bcd5454c47c7cc07eae9a1e
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Cancer Research
In Molecular Biology
In Oncology
Citations in the corpus
- Disruption of coordinated cardiac hypertrophy and angiogenesis contributes to the transition to heart failure. (2005, neutral): “Specifically, antiangiogenesis therapy for various diseases including cancer (53) could inhibit coronary angiogenesis and have adverse effects on the hearts of patients with cardiac hypertrophy that are at risk for heart failure (54).”
- Therapeutic targeting of the tumor microenvironment. (2005, positive): “…(Avastin) (Table 1), showed that in patients with metastatic colorectal cancer, there was a signifi cant survival benefit when combined with chemotherapy (Ferrara et al., 2004; Hurwitz et al., 2004), leading to the FDA approval of bevacizumab and renewing confidence in antiangio genic therapies.”
- VEGF in Signaling and Disease: Beyond Discovery and Development (2019, methodology): “, 1997) and was assessed for use in human clinical trials (Ferrara et al., 2004).”
- Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle. (2004, methodology): “Even the emergence of ‘targeted’ cancer therapeutics inhibiting tumor-specific proteins or pathways, such as anti-vascular endothelial growth factor (VEGF) antibody (1), has not eliminated problems of toxicity.”
- Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). (2010, background): “monoclonal antibody against vascular endothelial growth factor A (VEGF-A).(12) In a phase II trial of gemcitabine/bevacizumab in metastatic pancreatic cancer patients, Kindler et al(13) reported a response rate of 21%, a median OS of 8.”
- Ten years of anti-vascular endothelial growth factor therapy (2016, methodology): “…approved for the treatment of this disease by the FDA in July 2009. the same binding characteristics and inhibited the in vivo growth of human tumour cell lines with similar potency and efficacy to the original monoclonal antibody 65 and was assessed for use in human clinical trials 67 .”